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Abstract
Purpose of review—Despite the increased knowledge of osteocyte biology, the contribution of 
this most abundant bone cell to the development and progression of multiple myeloma in bone is 
practically unexplored.
Recent findings—Multiple myeloma bone disease is characterized by exacerbated bone 
resorption and the presence of osteolytic lesions that do not heal because of a concomitant 
reduction in bone formation. Osteocytes produce molecules that regulate both bone formation and 
resorption. Recent findings suggest that the life span of osteocytes is compromised in multiple 
myeloma patients with bone lesions. In addition, multiple myeloma cells affect the transcriptional 
profile of osteocytes by upregulating the production of pro-osteoclastogenic cytokines, stimulating 
osteoclast formation and activity. Further, patients with active multiple myeloma have elevated 
circulating levels of sclerostin, a potent inhibitor of bone formation which is specifically expressed 
by osteocytes in bone.
Summary—Understanding the contribution of osteocytes to the mechanisms underlying the 
skeletal consequences of multiple myeloma bone disease has the potential to provide important 
new therapeutic strategies that specifically target multiple myeloma–osteocyte interactions.
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Multiple myeloma is a plasma cell malignancy characterized by the accumulation of 
monoclonal plasma cells in the bone marrow and the presence of osteolytic lesions [1]. 
Multiple myeloma has the highest incidence of bone involvement among malignant 
diseases. It is estimated that up to 90% of patients with multiple myeloma have evidence of 
osteolysis in the form of generalized osteopenia or discrete lytic lesions, and up to 60% of 
multiple myeloma patients develop pathologic fractures [2,3]. Skeletal manifestations, 
which usually involve the axial skeleton, skull and femur, are the most prominent source of 
pain and disability in multiple myeloma.
Under physiologic conditions, interactions between cells present in the bone marrow 
microenvironment result in a balanced and coupled remodeling of bone, a lifelong process 
responsible for bone damage repair and mineral homeostasis [4]. Bone remodeling is 
performed by teams of bone-resorbing osteoclasts and bone-forming osteoblasts arranged 
within structures known as ‘bone remodeling compartments’ (BRCs) [5–7]. In the BRC, 
bone surface osteoclasts and osteoblasts are physically separated from the bone marrow 
cavity by a canopy of flat cells (Fig. 1). Functionally, this separation has been proposed to 
generate a unique microenvironment that facilitates spatial and temporal ‘coupled’ 
osteoclast resorption and osteoblast formation, minimizing the net change in bone volume 
during physiological bone remodeling. Although osteoblasts and osteoclast are major 
participants of the bone remodeling process, osteocytes are the central regulators of bone 
homeostasis [8▪]. Osteocytes are the most abundant bone cells, comprising more than 95% 
of all bone cells, compared with 1–2% osteoclasts and 5% osteoblasts. Despite that their cell 
bodies lie in lacunae carved within the mineral, osteocytes extensively communicate with 
each other and with cells on the bone surface and in the marrow through cytoplasmic 
projections that run within canaliculi [9]. This osteocytic lacunar-canalicular network allows 
direct cell-to-cell contact between osteocytes and cells near the bone surface and also 
distributes secreted molecules among all bone and marrow cells as well as into blood vessels 
to enter the general circulation. Osteocyte-derived molecules regulate the activity of both 
osteoblasts and osteoclasts by releasing paracrine factors, such as sclerostin (the product of 
the Sost gene) or the receptor activator of nuclear factor-kappa B ligand (RANKL), to 
locally regulate bone formation and resorption, respectively [10–12]. In addition, emerging 
evidence supports the notion that osteocytes are responsible for targeting bone remodeling to 
specific areas in bone [13–15]. In this regard, it has been proposed that apoptotic osteocytes 
signal to lining cells covering the bone surface, which lift up from bone into the bone 
marrow and form the canopy that encloses the BRC. Osteoclast precursors are then recruited 
to the BRC via marrow capillaries in which they mature to osteoclasts and resorb bone, 
initiating bone remodeling [6].
The bone marrow microenvironment in multiple myeloma is a major contributor to tumor 
growth and the bone destructive process. Bone remodeling is uncoupled in multiple 
myeloma and is characterized by generalized osteoclasts activation, which results in 
exacerbated bone resorption, and by suppressed osteoblast function resulting in a reduction 
in bone formation [16]. As a result, lytic lesions rarely heal, even when complete remission 
is attained. Recent evidence demonstrates that the BRC is disrupted in multiple myeloma, 
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supporting the notion that not only an exchange of soluble factors occurs, but also 
mechanisms involving direct cell-to-cell contact exist between multiple myeloma cells and 
bone cells (Fig. 1) [17]. The relevance of these cell-to-cell interactions to the in-vivo bone 
pathology in multiple myeloma is supported by in-vitro experiments and histological 
observations that show that extensive bone destruction occurs only in areas of the bones that 
are highly infiltrated with multiple myeloma cells, whereas bone resorption and formation 
are balanced in bones with lower tumor burden [18,19]. Interestingly, the biopsies with 
frequent disruptions in the BRC were also the ones that showed exacerbated resorption 
without matrix construction [7]. The significance of the cross-talk between multiple 
myeloma cells and osteoclast and osteoblasts has been a focus of recent investigations These 
studies found that multiple myeloma cells stimulate osteoclasts (OC) differentiation and 
activity through a series of potent osteoclasts effectors, such as RANKL, chemokine (C-C 
motif) ligand 3 (MIP-1), chemokine (C-X-C motif) ligand 12 (SDF-1), interleukin (IL)-1, 
IL-3, IL-6, vascular endothelial growth factor (VEGF) and tumor necrosis factor, whereas 
they reduce osteoblast numbers and activity through factors such as IL-7, dickkopf homolog 
1 (DKK1), secreted frizzled-related protein (sFRP), VLA-4/vascular cell adhesion molecule 
1 (VCAM-1), Fas ligand (FAsL), tumor necrosis factor (ligand) superfamily, member 10 
(TRAIL) and hepatocyte growth factor (HGF) [20–26]. Although our knowledge of 
osteocyte function has markedly increased during the last few years, there is a paucity of 
information about the cross-talk between multiple myeloma and osteocytes and how these 
interactions contribute to the development and progression of multiple myeloma. In this 
review, we examine the current findings regarding the role of osteocytes in multiple 
myeloma bone disease and the potential impact of determining the consequences of 
osteocyte interactions with myeloma cells that might result in the identification of additional 
targets for therapeutic development.
OSTEOCYTES AND THE CONTROL OF OSTEOCLAST ACTIVITY
Osteocyte apoptosis is spatially, temporally and functionally linked to bone remodeling 
partly as a result of the osteocyte cell death [27▪]. Several studies have shown that regions 
containing apoptotic osteocytes are targeted for bone resorption, which results in increased 
bone turnover [14,28,29]. Further, in-vitro experiments demonstrated that osteocyte 
apoptosis not only can induce recruitment of osteoclast precursors, but also their 
differentiation [29,30]. Interestingly, increased osteocyte apoptosis has been shown to be 
induced in vivo in areas of microdamage with bone disuse, glucocorticoid administration or 
estrogen deficiency-induced osteoporosis. Further, exclusive induction of apoptosis of 
osteocytes was sufficient to increase resorption and bone loss [13]. These findings suggest 
that osteocytes are involved in pathological conditions involving enhanced bone resorption 
[14,31,32]. A recent study reported similar findings in multiple myeloma patients [33▪▪]. In 
this study, multiple myeloma patients with bone lesions had fewer viable osteocytes than 
healthy controls or multiple myeloma patients without bone lesions, partly because of 
increased osteocyte apoptosis. In line with previous findings in other models, these 
investigators found a positive correlation between the number of apoptotic osteocytes and 
the number of osteoclasts in the areas examined. The mechanisms underlying osteoclasts 
recruitment and differentiation induced by osteocyte apoptosis are not fully understood. On 
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one hand, osteocyte death is commonly accompanied by large increases in RANKL 
expression, a molecule which not only promotes osteoclast differentiation, but also acts as 
an osteoclast precursor chemoattractant [34,35]. On the other hand, it is known that multiple 
myeloma cells affect the transcriptional profiles of osteocytes by upregulating the 
production of other osteoclastogenic cytokines such as interleukin-11 or MIP1α, thus 
increasing their pro-osteoclastogenic properties in an RANKL-independent fashion [33▪▪,
36]. Regardless of the mechanism involved, these results suggest that osteocyte apoptosis 
might be an early event in multiple myeloma development and progression resulting in 
enhanced osteoclast migration and production. In this regard, bisphosphonates, the standard 
of care for multiple myeloma-induced bone disease, interfere with osteoclast function and 
prevent osteocyte apoptosis [37]. However, the contribution of the latter to the overall 
beneficial effects of these drugs on multiple myeloma bone disease remains unknown.
Osteocytes produce molecules that regulate osteoclast production and activity and thus bone 
resorption. These molecules include the previously mentioned RANKL and macrophage 
colony stimulating factor 1 (M-CSF), as well as the antiosteoclastogenic cytokine 
osteoprotegerin (OPG; the RANKL decoy receptor). M-CSF is primarily involved in 
stimulating the proliferation of osteoclast progenitors, whereas RANKL is essential for their 
differentiation [38,39]. RANKL is expressed by many different cell types, including 
osteoblasts and osteocytes, stromal cells, B and T lymphocytes, synovial fibroblasts and 
hypertrophic chondrocytes [40]. However, only mice lacking RANKL in osteocytes (not 
osteoblasts or stromal osteoblastic cells) exhibit osteopetrosis, as a result of decreased 
osteoclast numbers [11,12]. These results indicate that osteocytes are a major source of 
RANKL and may play a key role in the enhanced resorption displayed in multiple myeloma.
In multiple myeloma, the balance of RANKL and OPG, key determinant for osteoclast 
differentiation, is disrupted, promoting activation of osteoclasts differentiation and 
consequently bone destruction [41,42,43▪▪]. Further, increased levels of soluble RANKL in 
multiple myeloma patients were shown to be associated with disease activity [44]. 
Consistent with an important role of this molecule in multiple myeloma bone disease, 
RANKL neutralization delayed multiple myeloma progression in mice [45]. Further, in 
patients with multiple myeloma, a monoclonal antibody capable of blocking RANKL 
(denosumab) reduced bone turnover [46]. However, the specific origin of the elevated 
RANKL levels in multiple myeloma bone disease is still unclear. RANKL is expressed at 
both the mRNA and the protein level in multiple myeloma cells themselves purified from 
bone marrow aspirates of multiple myeloma patients. Further, in-vitro experiments 
demonstrated that multiple myeloma cells induced differentiation of functional osteoclast 
precursors [44,47]. In addition, multiple myeloma cells induce RANKL expression in 
stromal/osteoblastic cells inducing an imbalance of RANKL/OPG ratio in favor of RANKL 
[48], and multiple myeloma cells also upregulate RANKL in T lymphocytes [49]. These 
results suggest that several cells can directly contribute to the pool of RANKL in bone. 
Recent results reported by our laboratory demonstrated for the first time that multiple 
myeloma cells upregulate RANKL expression in murine osteocytic cells, supporting the idea 
that osteocytes also contribute to the increased levels of RANKL [50▪▪]. In addition, we also 
found that OPG expression is downregulated in osteocytes by multiple myeloma cells, 
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leading to a more pro-osteoclastogenic RANKL/OPG ratio. In contrast, Giuliani et al. [33▪▪] 
reported that RANKL was not detected in the conditioned medium of the cocultures of 
human preosteocytes and multiple myeloma cells, suggesting that the contribution of 
osteocytes to the exacerbated bone resorption induced by multiple myeloma may also 
depend on other factors released by osteocytes. Further experiments are required to identify 
the specific role of osteocyte apoptosis and osteocytic RANKL in the early steps of multiple 
myeloma-induced bone disease.
REGULATION OF BONE FORMATION BY OSTEOCYTES
Osteocyte-derived molecules also regulate the activity of osteoblasts. Only osteocytes in 
bone secrete sclerostin, the product of the Sost gene, a potent inhibitor of bone formation 
and the first discovered and long-sought molecular mediator between osteocytes and bone 
surface cells [51]. Sclerostin antagonizes canonical Wnt signaling by binding to Wnt 
coreceptors LRP-4, LRP-5, and LRP-6, thus inhibiting wnt-dependent osteoblast 
differentiation and osteoblast survival [10,52–54]. Functional mutations of the Sost gene 
cause abnormal skeletal phenotypes in humans, characterized by high bone mineral density 
[55,56]. Likewise, Sost KO mice have a high bone mass phenotype characterized by 
increased bone formation [57]. Further, several clinical studies have shown that circulating 
sclerostin levels increase with age, suggesting that the increased production of sclerostin 
leads to the impairment of bone formation associated with aging [58]. In multiple myeloma, 
sclerostin levels are elevated in the serum or the plasma of patients, and correlate with the 
extent of bone disease and other adverse myeloma features [59,60,61▪▪]. Several recent 
studies reported that myeloma cells produce sclerostin or induce sclerostin expression in 
myeloma patients [62,63]; however, the specific contribution of sclerostin derived from 
osteocytes has not been explored. Giuliani et al. [33▪▪] did not find significant differences in 
sclerostin expression by osteocytes in multiple myeloma patients when compared with 
healthy controls, suggesting that higher sclerostin levels could be secreted directly by 
multiple myeloma cells rather than by osteocytes. However, we found that multiple 
myeloma cells promote upregulation of Sost mRNA levels in osteocytes, decreasing Wnt 
signaling and downregulating Wnt target genes such as OPG [50▪▪]. In contrast, we did not 
find Sost mRNA transcripts in the multiple myeloma cell line JJN3. Furthermore, we cannot 
exclude the possibility that apoptotic osteocytes in multiple myeloma contribute to the 
increased sclerostin levels, as it has been reported that proapoptotic factors may induce 
sclerostin expression in osteocytes [64]. These results suggest the possibility that osteocyte-
derived sclerostin contributes to the inhibition of the bone forming activity of osteoblasts in 
multiple myeloma bone disease. In addition to its role as a potent inhibitor of bone 
formation, recent findings suggest that sclerostin may also have a catabolic action, 
promoting osteoclast formation and activity, in an RANKL-dependent manner [65]. 
Although more experiments are needed to determine the mechanisms leading to the elevated 
levels of sclerostin in multiple myeloma bone disease and their consequences, Wnt proteins 
and their inhibitors offer a potential for the development of novel anabolic therapeutics in 
multiple myeloma.
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The potential role of osteocytes in multiple myeloma is underexplored. The studies reviewed 
in this article suggest that osteocytes may be responsible for many of the deleterious effects 
present in multiple myeloma bone disease (Fig. 2). Osteocytes are an important source of 
RANKL and sclerostin in bone, and the levels of these molecules are altered in multiple 
myeloma. The source of these molecules and the mechanisms of their aberrant production, 
as well as their roles in tumor growth, osteoclastogenesis and bone formation in multiple 
myeloma bone lesions still remain obscure. Findings demonstrating that multiple myeloma 
triggers osteocyte apoptosis, followed by increased osteoclast recruitment, bone destruction 
and poor bone quality, provide a new direction of mechanistic research that has not yet been 
explored. In addition, the knowledge that multiple myeloma cells regulate sclerostin, as well 
as Wnt signaling in osteocytes, raises the possibility of using currently available tools that 
target these pathways as new therapeutic approaches for multiple myeloma, and eventually 
other cancers targeting bone.
Acknowledgments
This work was supported in part by the National Institutes of Health Grants, VA Merit Review (Indiana-CTSI) and 
The Gideon and Sevgi Rodan Fellowship (International Bone and Mineral Society).
REFERENCES AND RECOMMENDED READING
Papers of particular interest, published within the annual period of review, have been 
highlighted as:
▪ of special interest
▪▪ of outstanding interest
1. Roodman GD. Pathogenesis of myeloma bone disease. Leukemia. 2009; 23:435–441. [PubMed: 
19039321] 
2. Roodman GD. Pathogenesis of myeloma bone disease. Blood Cells Mol Dis. 2004; 32:290–292. 
[PubMed: 15003820] 
3. Greenberg AJ, Rajkumar SV, Therneau TM, et al. Relationship between initial clinical presentation 
and the molecular cytogenetic classification of myeloma. Leukemia. 2014; 28:398–403. [PubMed: 
24005246] 
4. Allen, MR.; Burr, DB. Bone modeling and remodeling. In: Burr, D.; Allen, M., editors. Basic and 
Applied Bone Biology. 1. San Diego, United States: Elsevier; 2014. p. 75-90.
5. Hauge EM, Qvesel D, Eriksen EF, et al. Cancellous bone remodeling occurs in specialized 
compartments lined by cells expressing osteoblastic markers. J Bone Miner Res. 2001; 16:1575–
1582. [PubMed: 11547826] 
6. Eriksen EF, Eghbali-Fatourechi GZ, Khosla S. Remodeling and vascular spaces in bone. J Bone 
Miner Res. 2007; 22:1–6. [PubMed: 17040170] 
7. Andersen TL, Sondergaard TE, Skorzynska KE, et al. A physical mechanism for coupling bone 
resorption and formation in adult human bone. Am J Pathol. 2009; 174:239–247. [PubMed: 
19095960] 
8▪. Bellido T. Osteocyte-driven bone remodeling. Calcif Tissue Int. 2013; 94:25–34. This article 
provides a detailed review of osteocytes in bone remodeling. [PubMed: 24002178] 
9. Bonewald LF. The amazing osteocyte. J Bone Miner Res. 2011; 26:229–238. [PubMed: 21254230] 
10. Poole KE, Van Bezooijen RL, Loveridge N, et al. Sclerostin is a delayed secreted product of 
osteocytes that inhibits bone formation. FASEB J. 2005; 19:1842–1844. [PubMed: 16123173] 
Delgado-Calle et al. Page 6













11. Nakashima T, Hayashi M, Fukunaga T, et al. Evidence for osteocyte regulation of bone 
homeostasis through RANKL expression. Nat Med. 2011; 17:1231–1234. [PubMed: 21909105] 
12. Xiong J, Onal M, Jilka RL, et al. Matrix-embedded cells control osteoclast formation. Nat Med. 
2011; 17:1235–1241. [PubMed: 21909103] 
13. Tatsumi S, Ishii K, Amizuka N, et al. Targeted ablation of osteocytes induces osteoporosis with 
defective mechanotransduction. Cell Metab. 2007; 5:464–475. [PubMed: 17550781] 
14. Aguirre JI, Plotkin LI, Stewart SA, et al. Osteocyte apoptosis is induced by weightlessness in mice 
and precedes osteoclast recruitment and bone loss. J Bone Min Res. 2006; 21:605–615.
15. Bellido T. Osteocyte apoptosis induces bone resorption and impairs the skeletal response to 
weightlessness. BoneKEy-Osteovision. 2007; 4:252–256.
16. Roodman GD. Targeting the bone microenvironment in multiple myeloma. J Bone Miner Metab. 
2010; 28:244–250. [PubMed: 20127498] 
17. Andersen TL, Soe K, Sondergaard TE, et al. Myeloma cell-induced disruption of bone remodelling 
compartments leads to osteolytic lesions and generation of osteoclast-myeloma hybrid cells. Br J 
Haematol. 2010; 148:551–561. [PubMed: 19919653] 
18. Taube T, Beneton MNC, McCloskey EV, et al. Abnormal bone remodelling in patients with 
myelomatosis and normal biochemical indices of bone resorption. Eur J Haematol. 1992; 49:192–
198. [PubMed: 1464362] 
19. Bataille R, Chappard D, Basle M. Excessive bone resorption in human plasmacytomas: direct 
induction by tumour cells in vivo. Br J Haematol. 1995; 90:721–724. [PubMed: 7647018] 
20. Silvestris F, Cafforio P, Tucci M, et al. Upregulation of osteoblast apoptosis by malignant plasma 
cells: a role in myeloma bone disease. Br J Haematol. 2003; 122:39–52. [PubMed: 12823344] 
21. Gunn WG, Conley A, Deininger L, et al. A crosstalk between myeloma cells and marrow stromal 
cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic 
bone disease and tumor progression in multiple myeloma. Stem Cells. 2006; 24:986–991. 
[PubMed: 16293576] 
22. Choi SJ, Oba T, Callander NS, et al. AML-1A and AML-1B regulation of MIP-1alpha expression 
in multiple myeloma. Blood. 2003; 101:3778–3783. [PubMed: 12560229] 
23. Silbermann R, Bolzoni M, Storti P, et al. Bone marrow monocyte/macrophage derived activin a 
mediates the osteoclastogenic effect of IL-3 in multiple myeloma. Leukemia. 2014; 28:951–954. 
[PubMed: 24369304] 
24. Ehrlich LA, Roodman GD. The role of immune cells and inflammatory cytokines in Paget’s 
disease and multiple myeloma. Immunol Rev. 2005; 208:252–266. [PubMed: 16313353] 
25. Giuliani N, Colla S, Morandi F, et al. Myeloma cells block RUNX2/CBFA1 activity in human 
bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood. 
2005; 106:2472–2483. [PubMed: 15933061] 
26. Giuliani N, Colla S, Rizzoli V. New insight in the mechanism of osteoclast activation and 
formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand [RANKL]. 
Exp Hematol. 2004; 32:685–691. [PubMed: 15308315] 
27▪. Plotkin LI. Apoptotic osteocytes and the control of targeted bone resorption. Curr Osteoporos 
Rep. 2014; 12:121–126. This article reviews targeted bone remodeling by osteocytes apoptosis. 
[PubMed: 24470254] 
28. Cardoso L, Herman BC, Verborgt O, et al. Osteocyte apoptosis controls activation of intracortical 
resorption in response to bone fatigue. J Bone Miner Res. 2009; 24:597–605. [PubMed: 19049324] 
29. Noble B. Microdamage and apoptosis. Eur J Morphol. 2005; 42:91–98. [PubMed: 16123028] 
30. O’Brien FJ, Brennan O, Kennedy OD, et al. Microcracks in cortical bone: how do they affect bone 
biology? Curr Osteoporos Rep. 2005; 3:39–45. [PubMed: 16036100] 
31. Kennedy OD, Herman BC, Laudier DM, et al. Activation of resorption in fatigue-loaded bone 
involves both apoptosis and active pro-osteoclastogenic signaling by distinct osteocyte 
populations. Bone. 2012; 50:1115–1122. [PubMed: 22342796] 
32. Brennan O, Kennedy OD, Lee TC, et al. Effects of estrogen deficiency and bisphosphonate therapy 
on osteocyte viability and microdamage accumulation in an ovine model of osteoporosis. J Orthop 
Res. 2011; 29:419–424. [PubMed: 20886644] 
Delgado-Calle et al. Page 7













33▪▪. Giuliani N, Ferretti M, Bolzoni M, et al. Increased osteocyte death in multiple myeloma patients: 
role in myeloma-induced osteoclast formation. Leukemia. 2012; 26:1391–1401. This article 
reports increased osteocyte apoptosis in multiple myeloma patients with bone lesions. In 
addition, the authors explored some of the consequences and mechanisms involved in multiple 
myeloma-induced osteocyte apoptosis. [PubMed: 22289923] 
34. Al-Dujaili SA, Lau E, Al-Dujaili H, et al. Apoptotic osteocytes regulate osteoclast precursor 
recruitment and differentiation in vitro. J Cell Biochem. 2011; 112:2412–2423. [PubMed: 
21538477] 
35. Bivi N, Condon KW, Allen MR, et al. Cell autonomous requirement of connexin 43 for osteocyte 
survival: consequences for endocortical resorption and periosteal bone formation. J Bone Min Res. 
2012; 27:374–389.
36. Eisenberger S, Ackermann K, Voggenreiter G, et al. Metastases and multiple myeloma generate 
distinct transcriptional footprints in osteocytes in vivo. J Pathol. 2008; 214:617–626. [PubMed: 
18266311] 
37. Bellido T, Plotkin LI. Novel actions of bisphosphonates in bone: preservation of osteoblast and 
osteocyte viability. Bone. 2011; 49:50–55. [PubMed: 20727997] 
38. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte 
development and lymph-node organogenesis. Nature. 1999; 397:315–323. [PubMed: 9950424] 
39. Yoshida H, Hayashi S-I, Kunisada T, et al. The murine mutation osteopetrosis is in the coding 
region of the macrophage colony stimulating factor gene. Nature. 1990; 345:442–444. [PubMed: 
2188141] 
40. O’Brien CA, Nakashima T, Takayanagi H. Osteocyte control of osteoclastogenesis. Bone. 2013; 
54:258–263. [PubMed: 22939943] 
41. Pearse RN, Sordillo EM, Yaccoby S, et al. Multiple myeloma disrupts the TRANCE/
osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc 
Natl Acad Sci U S A. 2001; 98:11581–11586. [PubMed: 11562486] 
42. Giuliani N, Bataille R, Mancini C, et al. Myeloma cells induce imbalance in the osteoprotegerin/
osteoprotegerin ligand system in the human bone marrow environment. Blood. 2001; 98:3527–
3533. [PubMed: 11739153] 
43▪▪. Schmiedel BJ, Scheible CA, Nuebling T, et al. RANKL expression, function, and therapeutic 
targeting in multiple myeloma and chronic lymphocytic leukemia. Cancer Res. 2013; 73:683–
694. This article reviews RANKL biology in multiple myeloma. [PubMed: 23139212] 
44. Jakob C, Goerke A, Terpos E, et al. Serum levels of total-RANKL in multiple myeloma. Clin 
Lymphoma Myeloma. 2009; 9:430–435. [PubMed: 19951882] 
45. Sordillo EM, Pearse RN. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma. Cancer. 
2003; 97(Suppl 3):802–812. [PubMed: 12548579] 
46. Vij R, Horvath N, Spencer A, et al. An open-label, phase 2 trial of denosumab in the treatment of 
relapsed or plateau-phase multiple myeloma. Am J Hematol. 2009; 84:650–656. [PubMed: 
19714603] 
47. Farrugia AN, Atkins GJ, To LB, et al. Receptor activator of nuclear factor-kappaB ligand 
expression by human myeloma cells mediates osteoclast formation in vitro and correlates with 
bone destruction in vivo. Cancer Res. 2003; 63:5438–5445. [PubMed: 14500379] 
48. Michigami T, Shimizu N, Williams PJ, et al. Cell-cell contact between marrow stromalcells and 
myeloma cells via VCAM-1 and alpha[4]beta[1]-integrin enhances production of osteoclast-
stimulating activity. Blood. 2000; 96:1953–1960. [PubMed: 10961900] 
49. Giuliani N, Colla S, Sala R, et al. Human myeloma cells stimulate the receptor activator of nuclear 
factor-kappa B ligand [RANKL] in T lymphocytes: a potential role in multiple myeloma bone 
disease. Blood. 2002; 100:4615–4621. [PubMed: 12393684] 
50▪▪. Delgado-Calle J, Bellido T, Roodman GD. Direct cell-to-cell interactions between osteocytes and 
multiple myeloma [MM] cells upregulate Sost and downregulate OPG expression in osteocytes: 
evidence for osteocytic contributions to MM-induced bone disease. Blood. 2013; 122:3140. This 
study reports for the first time direct regulation of RANKL, OPG and Sost in osteocytes by 
multiple myeloma MM cells. 
Delgado-Calle et al. Page 8













51. Weivoda MM, Oursler MJ. Developments in sclerostin biology: regulation of gene expression, 
mechanisms of action, and physiological functions. Curr Osteoporos Rep. 2014; 12:107–114. 
[PubMed: 24477413] 
52. Van Bezooijen RL, Roelen BA, Visser A, et al. Sclerostin is an osteocyte-expressed negative 
regulator of bone formation, but not a classical BMP antagonist. J Exp Med. 2004; 199:805–814. 
[PubMed: 15024046] 
53. Sutherland MK, Geoghegan JC, Yu C, et al. Sclerostin promotes the apoptosis of human 
osteoblastic cells: a novel regulation of bone formation. Bone. 2004; 35:828–835. [PubMed: 
15454089] 
54. Li X, Zhang Y, Kang H, et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt 
signaling. J Biol Chem. 2005; 280:19883–19887. [PubMed: 15778503] 
55. Wergedal JE, Veskovic K, Hellan M, et al. Patients with Van Buchem disease, an osteosclerotic 
genetic disease, have elevated bone formation markers, higher bone density, and greater derived 
polar moment of inertia than normal. J Clin Endocrinol Metab. 2003; 88:5778–5783. [PubMed: 
14671168] 
56. Balemans W, Patel N, Ebeling M, et al. Identification of a 52 kb deletion downstream of the SOST 
gene in patients with van Buchem disease. J Med Genet. 2002; 39:91–97. [PubMed: 11836356] 
57. Li X, Niu Q-T, Sun N, et al. Mice lacking sclerostin have increased bone formation and bone 
strength. Calcif Tissue Int. 2007; 80(Suppl 1):S24.
58. Ke HZ, Richards WG, Li X, et al. Sclerostin and Dickkopf-1 as therapeutic targets in bone 
diseases. Endocr Rev. 2012; 33:747–783. [PubMed: 22723594] 
59. Terpos E, Christoulas D, Katodritou E, et al. Elevated circulating sclerostin correlates with 
advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction 
postbortezomib monotherapy. Int J Cancer. 2012; 131:1466–1471. [PubMed: 22052418] 
60. Brunetti G, Oranger A, Mori G, et al. Sclerostin is overexpressed by plasma cells from multiple 
myeloma patients. Ann N Y Acad Sci. 2011; 1237:19–23. [PubMed: 22082361] 
61▪▪. Wang XT, He YC, Zhou SY, et al. Bone marrow plasma macrophage inflammatory protein 
protein-1 alpha [MIP-1 alpha] and sclerostin in multiple myeloma: relationship with bone disease 
and clinical characteristics. Leuk Res. 2014; 38:525–531. This article reports elevated sclerostin 
levels in the serum of multiple myeloma patients and the potential relationship with multiple 
myeloma-induced bone disease. [PubMed: 24656650] 
62. Colucci S, Brunetti G, Oranger A, et al. Myeloma cells suppress osteoblasts through sclerostin 
secretion. Blood Cancer J. 2011; 1:e27. [PubMed: 22829171] 
63. Habibi H, Abroun S, Hajifathali A, et al. Osteogenic inhibition in multiple myeloma. Cell J. 2013; 
15:266–271. [PubMed: 24027669] 
64. Mabilleau G, Mieczkowska A, Edmonds ME. Thiazolidinediones induce osteocyte apoptosis and 
increase sclerostin expression. Diabet Med. 2010; 27:925–932. [PubMed: 20653751] 
65. Wijenayaka AR, Kogawa M, Lim HP, et al. Sclerostin stimulates osteocyte support of osteoclast 
activity by a RANKL-dependent pathway. PLoS One. 2011; 6:e25900. [PubMed: 21991382] 
Delgado-Calle et al. Page 9














• Osteocytes are key regulators of bone remodelling, and their role in multiple 
myeloma bone disease is largely unknown.
• Osteocyte viability is decreased in multiple myeloma patients with bone lesions.
• Crosstalk between multiple myeloma cells and osteocytes induces profound 
changes in osteocytic gene expression.
• Understanding multiple myeloma–osteocyte interactions has the potential to 
develop new therapeutic strategies.
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The BRC in multiple myeloma. Osteocytes sense the need for bone resorption and send 
signals to lining cells, which retract from the bone surface to form the BRC, and secrete 
molecules that regulate osteoblast and osteoclast formation and activity. Osteoclast 
precursors are transported to the BRC by marrow capillaries, differentiate to mature 
osteoclasts and initiate bone remodeling. Osteoblasts precursors from the bone marrow or 
the circulation differentiate into mature, bone synthesizing cells in response to factors 
released from the bone matrix by resorption. In multiple myeloma, the canopy of lining cells 
that separate the bone marrow from the active bone remodeling areas on bone is disrupted. 
Multiple myeloma cells are then able to enter in close contact with osteoclasts, osteoblasts 
and osteocytes and modulate their function (dotted lines). BRC, bone remodeling 
compartment; MM, multiple myeloma; OPG, osteoprotegerin; RANKL, receptor activator 
of nuclear factor-kappa B ligand.
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Potential role of osteocytes in multiple myeloma bone disease. Interactions between 
osteocytes and multiple myeloma cells within the BRC modulate critical signaling pathways 
and mediators responsible for bone resorption and bone formation. Osteocyte apoptosis is 
markedly increased in multiple myeloma patients with bone lesions and results in targeted 
osteoclast recruitment. The RANKL/OPG ratio in osteocytes is also elevated by multiple 
myeloma cells because of a combination of downregulation of OPG and upregulation of 
RANKL expression potentially increasing osteoclast differentiation. In addition, increased 
Sost/Sclerostin in osteocytes induced by multiple myeloma could contribute to the decreased 
bone formation that characterizes multiple myeloma-induced bone disease. MM, multiple 
myeloma; OPG, osteoprotegerin; RANKL, receptor activator of nuclear factor-kappa B 
ligand.
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